SI2026769T1 - Dvoplastna tableta za preprečevanje kardiovaskularnih dogodkov - Google Patents
Dvoplastna tableta za preprečevanje kardiovaskularnih dogodkovInfo
- Publication number
- SI2026769T1 SI2026769T1 SI200730263T SI200730263T SI2026769T1 SI 2026769 T1 SI2026769 T1 SI 2026769T1 SI 200730263 T SI200730263 T SI 200730263T SI 200730263 T SI200730263 T SI 200730263T SI 2026769 T1 SI2026769 T1 SI 2026769T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cardiovascular events
- bilayer tablet
- preventing cardiovascular
- preventing
- bilayer
- Prior art date
Links
- 230000007211 cardiovascular event Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200601355A ES2300188B1 (es) | 2006-05-24 | 2006-05-24 | Comprimido bicapa para la prevencion de los accidentes cardiovasculares. |
EP07725528A EP2026769B1 (en) | 2006-05-24 | 2007-05-24 | Bilayer tablet for preventing cardiovascular events |
PCT/EP2007/004631 WO2007134870A1 (en) | 2006-05-24 | 2007-05-24 | Bilayer tablet for preventing cardiovascular events |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2026769T1 true SI2026769T1 (sl) | 2010-08-31 |
Family
ID=38556680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200730263T SI2026769T1 (sl) | 2006-05-24 | 2007-05-24 | Dvoplastna tableta za preprečevanje kardiovaskularnih dogodkov |
Country Status (24)
Country | Link |
---|---|
US (1) | US20090196922A1 (sl) |
EP (1) | EP2026769B1 (sl) |
JP (1) | JP2009537583A (sl) |
KR (1) | KR20090020577A (sl) |
CN (1) | CN101453992A (sl) |
AR (1) | AR061047A1 (sl) |
AT (1) | ATE460924T1 (sl) |
AU (1) | AU2007253580B2 (sl) |
BR (1) | BRPI0712267A2 (sl) |
CA (1) | CA2652838A1 (sl) |
CY (1) | CY1110097T1 (sl) |
DE (1) | DE602007005372D1 (sl) |
DK (1) | DK2026769T3 (sl) |
ES (2) | ES2300188B1 (sl) |
HK (1) | HK1129577A1 (sl) |
MX (1) | MX2008014782A (sl) |
NO (1) | NO20084998L (sl) |
PL (1) | PL2026769T3 (sl) |
PT (1) | PT2026769E (sl) |
RU (1) | RU2445088C2 (sl) |
SI (1) | SI2026769T1 (sl) |
TW (1) | TW200812647A (sl) |
UY (1) | UY30365A1 (sl) |
WO (1) | WO2007134870A1 (sl) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100055180A1 (en) * | 2007-10-10 | 2010-03-04 | Mallinckrodt Baker, Inc. | Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof |
MX339320B (es) * | 2007-10-10 | 2016-05-20 | Avantor Performance Mat Inc | Excipiente basado en celulosa microcristalina granular con alta funcionalidad y directamente comprimible, procedimiento de elaboracion y uso del mismo. |
CN102711739B (zh) * | 2009-11-13 | 2015-12-16 | 阿斯利康(瑞典)有限公司 | 双层片剂 |
US20130165459A1 (en) * | 2010-01-12 | 2013-06-27 | Norvartis Pharma Ag | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
BR112014024382B1 (pt) | 2012-04-18 | 2022-08-09 | SpecGx LLC | Composições farmacêuticas de contenção de abuso de liberação imediata e seu processo de preparação |
WO2014059512A1 (en) * | 2012-10-15 | 2014-04-24 | Isa Odidi | Oral drug delivery formulations |
WO2014152296A1 (en) | 2013-03-15 | 2014-09-25 | Mallinckrodt Llc | Abuse deterrent solid dosage form for immediate release with functional score |
PT3164117T (pt) | 2014-07-03 | 2023-12-12 | SpecGx LLC | Formulações de libertação imediata de dissuasão de abuso compreendendo polissacáridos não celulósicos |
EP3313378A1 (en) * | 2015-06-26 | 2018-05-02 | AbbVie Inc. | Solid pharmaceutical compositions for treating hcv |
JP7133466B2 (ja) * | 2015-07-17 | 2022-09-08 | アッヴィ・インコーポレイテッド | Hcvを処置するための固体医薬組成物 |
TWI789391B (zh) * | 2017-04-25 | 2023-01-11 | 日商大塚製藥股份有限公司 | 具有可攝取事件標記的利欣諾普組成物 |
CA3112030A1 (en) | 2018-09-25 | 2020-04-02 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US20010014352A1 (en) * | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
AU4671101A (en) * | 2000-04-10 | 2001-10-23 | Malcolm R. Law | Formulation for the prevention of cardiovascular disease |
US6462174B1 (en) * | 2001-06-25 | 2002-10-08 | Astrazeneca Ab | Amorphous compound |
US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
WO2003066752A1 (fr) * | 2002-02-05 | 2003-08-14 | Ricoh Company Ltd. | Encre pour impression a jet d'encre, jeu d'encres, cartouche d'encre, imprimante et procede d'impression |
CA2379887C (en) * | 2002-04-09 | 2004-01-20 | Bernard Charles Sherman | Stable tablets comprising simvastatin |
AU2004261212B2 (en) * | 2003-07-28 | 2011-01-27 | Dr. Reddy's Laboratories Ltd. | Treatment and prevention of cardiovascular events |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
US8987322B2 (en) * | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
WO2007020079A2 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | Orally disintegratable simvastatin tablets |
-
2006
- 2006-05-24 ES ES200601355A patent/ES2300188B1/es not_active Expired - Fee Related
-
2007
- 2007-05-21 AR ARP070102182A patent/AR061047A1/es not_active Application Discontinuation
- 2007-05-21 TW TW096118038A patent/TW200812647A/zh unknown
- 2007-05-24 CA CA002652838A patent/CA2652838A1/en not_active Abandoned
- 2007-05-24 BR BRPI0712267-5A patent/BRPI0712267A2/pt not_active IP Right Cessation
- 2007-05-24 JP JP2009511413A patent/JP2009537583A/ja not_active Abandoned
- 2007-05-24 EP EP07725528A patent/EP2026769B1/en not_active Not-in-force
- 2007-05-24 AT AT07725528T patent/ATE460924T1/de active
- 2007-05-24 PL PL07725528T patent/PL2026769T3/pl unknown
- 2007-05-24 AU AU2007253580A patent/AU2007253580B2/en not_active Ceased
- 2007-05-24 DE DE602007005372T patent/DE602007005372D1/de active Active
- 2007-05-24 SI SI200730263T patent/SI2026769T1/sl unknown
- 2007-05-24 US US12/301,432 patent/US20090196922A1/en not_active Abandoned
- 2007-05-24 ES ES07725528T patent/ES2342905T3/es active Active
- 2007-05-24 WO PCT/EP2007/004631 patent/WO2007134870A1/en active Application Filing
- 2007-05-24 MX MX2008014782A patent/MX2008014782A/es active IP Right Grant
- 2007-05-24 PT PT07725528T patent/PT2026769E/pt unknown
- 2007-05-24 KR KR1020087028617A patent/KR20090020577A/ko not_active Application Discontinuation
- 2007-05-24 DK DK07725528.9T patent/DK2026769T3/da active
- 2007-05-24 UY UY30365A patent/UY30365A1/es unknown
- 2007-05-24 RU RU2008151105/15A patent/RU2445088C2/ru not_active IP Right Cessation
- 2007-05-24 CN CNA2007800189488A patent/CN101453992A/zh active Pending
-
2008
- 2008-11-28 NO NO20084998A patent/NO20084998L/no unknown
-
2009
- 2009-08-24 HK HK09107747.2A patent/HK1129577A1/xx not_active IP Right Cessation
-
2010
- 2010-06-16 CY CY20101100557T patent/CY1110097T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2007253580A1 (en) | 2007-11-29 |
MX2008014782A (es) | 2008-11-28 |
PT2026769E (pt) | 2010-06-11 |
PL2026769T3 (pl) | 2010-09-30 |
HK1129577A1 (en) | 2009-12-04 |
ES2342905T3 (es) | 2010-07-16 |
JP2009537583A (ja) | 2009-10-29 |
BRPI0712267A2 (pt) | 2012-01-17 |
CA2652838A1 (en) | 2007-11-29 |
NO20084998L (no) | 2009-02-23 |
ES2300188A1 (es) | 2008-06-01 |
WO2007134870A1 (en) | 2007-11-29 |
DK2026769T3 (da) | 2010-07-19 |
RU2445088C2 (ru) | 2012-03-20 |
DE602007005372D1 (de) | 2010-04-29 |
ATE460924T1 (de) | 2010-04-15 |
US20090196922A1 (en) | 2009-08-06 |
CN101453992A (zh) | 2009-06-10 |
RU2008151105A (ru) | 2010-06-27 |
AU2007253580B2 (en) | 2012-03-22 |
CY1110097T1 (el) | 2015-01-14 |
AR061047A1 (es) | 2008-07-30 |
UY30365A1 (es) | 2007-08-31 |
EP2026769A1 (en) | 2009-02-25 |
TW200812647A (en) | 2008-03-16 |
EP2026769B1 (en) | 2010-03-17 |
ES2300188B1 (es) | 2009-05-01 |
KR20090020577A (ko) | 2009-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1129577A1 (en) | Bilayer tablet for preventing cardiovascular events | |
IL206171A0 (en) | Tablet dispenser | |
EP1948543A4 (en) | DISPENSER OF TABLETS | |
HK1127356A1 (en) | Pharmaceutical compounds | |
GB0608820D0 (en) | Pharmaceutical compounds | |
AU309481S (en) | A tablet | |
EP1905430A4 (en) | TABLET | |
GB2449505B (en) | Tablet dispenser | |
EP2114381A4 (en) | ORAL TRIPLE CONTINUOUS RELEASE TABLET | |
EP1968562A4 (en) | MULTILAYER TABLET | |
SI2040684T1 (sl) | Večenotne tablete | |
EP2057985A4 (en) | DRAGEE | |
ZA200904654B (en) | Tablet formulation | |
GB0605104D0 (en) | Tablet dispenser | |
GB0608176D0 (en) | Pharmaceutical Compounds | |
GB0608184D0 (en) | Pharmaceutical compounds | |
GB0608465D0 (en) | Tablet dispenser | |
EP1867324A4 (en) | COMPRESSED | |
GB0608264D0 (en) | Pharmaceutical compounds | |
EP2050456A4 (en) | COMPRESSED | |
GB0625682D0 (en) | Pharmaceutical compounds | |
GB0622892D0 (en) | Pharmaceutical compounds | |
GB0620112D0 (en) | Detergent tablets | |
GB0608175D0 (en) | Pharmaceutical Compounds | |
AU305389S (en) | Tablet dispenser |